$0.72
0.00%
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US64132R1077
Symbol
MTVA
Sector
Industry

NeuroBo Pharmaceuticals Inc Stock price

$0.72
-0.03 4.58% 1M
-1.29 64.28% 6M
-1.31 64.63% YTD
-3.94 84.59% 1Y
-139.49 99.49% 3Y
-1,818.48 99.96% 5Y
-55,199.28 100.00% 10Y
-55,199.28 100.00% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
+0.00 0.00%
ISIN
US64132R1077
Symbol
MTVA
Sector
Industry

Key metrics

Basic
Market capitalization
$14.1m
Enterprise Value
$2.9m
Net debt
positive
Cash
$11.2m
Shares outstanding
8.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
48.8%
Return on Equity
-347.9%
ROCE
-584.0%
ROIC
541.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-25.8m | -
EBIT
$-25.8m | $-28.1m
Net Income
$-24.6m | $-12.7m
Free Cash Flow
$-23.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-27.4% | -
EBIT
-27.5% | 2.6%
Net Income
-48.1% | 53.9%
Free Cash Flow
-56.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.4
FCF per Share
$-2.7
Short interest
2.2%
Employees
-
Rev per Employee
-
Show more

Is NeuroBo Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

NeuroBo Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast:

Buy
89%
Hold
11%

Financial data from NeuroBo Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.84 6.84
0% 0%
-
- Research and Development Expense 19 19
41% 41%
-
-26 -26
27% 27%
-
- Depreciation and Amortization 0.02 0.02
100% 100%
-
EBIT (Operating Income) EBIT -26 -26
27% 27%
-
Net Profit -25 -25
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about NeuroBo Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroBo Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
5 days ago
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass. , July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog ...
Neutral
PRNewsWire
23 days ago
CAMBRIDGE, Mass. , June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of pre-clinical data on DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, demonstrating  additive hepatoprotective effects in combination with Efruxifermin, a fibroblast growth fact...
Neutral
GlobeNewsWire
about one month ago
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
More NeuroBo Pharmaceuticals Inc News

Company Profile

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.

Head office United States
CEO Hyung-Heon Kim
Founded 2014
Website metaviatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today